Renal Cell Carinoma

Hybrid Cell Vaccine Used to Treat Patients

Published in Gene Therapy Weekly, November 10th, 1997

Fourteen patients with advanced renal cell carcinoma (RCC) underwent vaccination with a hybrid cell cancer vaccine created at the University of Tubingen, Germany.

RCC is an immunogenic malignancy. Its antitumor immune responses are mediated primarily by major histocompatibility cell (MHC) class I antigens which stimulate T cells. However, for the initiation of CD4⁺ T cells, MHC class II antigens are required. These T cells induce proliferation of CD8 positive cytotoxic T lymphocytes (CTL), which act as effectors on tumor target cells. RCC generally presents MHC class I antigens but lacks MHC class II antigens. Both MHC antigens must be present on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-11-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry